-+ 0.00%
-+ 0.00%
-+ 0.00%

Ocugen to present 12-month Phase 2 ArMaDa trial results for OCU410 gene therapy in geographic atrophy at AAO 2026

PUBT·09/30/2026 11:08:10
Ocugen to present 12-month Phase 2 ArMaDa trial results for OCU410 gene therapy in geographic atrophy at AAO 2026
  • Ocugen flagged upcoming presentations of clinical trial results for its modifier gene therapies in eye diseases.
  • Phase 2 ArMaDa trial readouts for OCU410 in geographic atrophy are scheduled for Oct. 9 and Oct. 11, 2026.
  • Management framed the ArMaDa update as covering safety and efficacy outcomes over 12 months, with no metrics disclosed.
  • Phase 1/2 GARDian1 results for OCU410ST in Stargardt disease will also be presented in early October 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocugen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609300702PRIMZONEFULLFEED9836569) on September 30, 2026, and is solely responsible for the information contained therein.